CIRM Funded Clinical Trials
Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients
Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients
Mehrdad Abedi
Disease Area:
HIV-related Lymphoma
Investigator:
Institution:
CIRM Grant:
Award Value:
$8,414,265
Trial Sponsor:
Trial Stage:
Phase 1/2
Trial Status:
Recruiting
Targeted Enrollment:
18
ClinicalTrials.gov ID:
Details:
A team at UC Davis is taking a patient’s blood forming stem cells and inserting three anti-HIV genes into them and then returning them to the individual to help rebuild their immune system. The anti-HIV genes are then passed on to all new immune system cells, which makes them resistant to HIV. Because AIDS-related lymphoma is linked to the constant immune cell stimulation caused by HIV infection, getting rid of the virus should prevent return of the cancer.
Design:
Open label, single arm study.
Goal:
Safety. Efficacy - immune reconstitution, viral load and HIV status.
